The Evolving Landscape of Omics-based Biomarkers in Precision Therapeutics

Precision therapeutics embraces molecular signatures including gene sets as well as the epigenome, transcriptome, proteome, metabolome and microbiome, which can synergistically act as markers of drug response. Application of precision therapeutics from bench to bedside leverages different layers of -omics, from gene to protein, to improve drug efficacy and reduce adverse events incidence in all areas of medicine where drugs are prescribed. The landscape of omics-based biomarkers is rapidly evolving and holds the promise to revolutionize the traditional therapeutic decision-making. Identification of novel biomarkers with potential use in diagnosis, prognosis, patient stratification and drug design can dramatically improve individual response to pharmacotherapy, placing the patient at the center of therapeutic decisions.This Research Topic, developed in collaboration with the Hellenic Society for Basic and Clinical Pharmacology (HSBCP) and launched alongside its 13th Panhellenic Congress in Patras, aims to explore the applications of omics-based biomarkers in advancing the field of precision therapeutics. The goal is to examine how novel genomic, pharmacogenomic, epigenomic, transcriptomic and metabolomic biomarkers can enhance the prediction of therapeutic outcomes, improve disease risk assessment, and facilitate the transition to more targeted and efficient therapies in different fields of medicine. We also seek to synthetize the use of -omic biomarkers as a novel tool for drug repurposing, expanding the frontiers of individualized therapy and transforming healthcare delivery.We invite submissions that move the field from candidate discovery toward clinical action across therapeutic areas including oncology, cardiovascular, neurological, respiratory, metabolic, infectious, and immune-mediated diseases.We welcome Original Research, Reviews, Mini-Reviews, Methods, Perspectives, and Clinical Trial articles on themes including:- Pharmacogenomics and pharmacotranscriptomics for predicting drug response, dosing, toxicity, and adverse drug reactions- Multi-omics integration and AI/machine learning approaches for biomarker discovery, validation, drug repurposing and clinical translation- Emerging biomarker modalities: liquid biopsy, extracellular vesicles, epigenomic, and microbiome signatures- Companion diagnostics, stratified medicine, and regulatory pathways to clinical implementation- Biomarkers for advanced therapeutics — including cell, gene, and RNA-based therapiesContributions that bridge fundamental discovery and clinical application are especially encouraged, as are studies addressing underrepresented populations, paediatric and geriatric pharmacology, and implementation experience from real-world health systems.Together with HSBCP, this collection sets out to map where omics-based biomarkers are genuinely changing patient care and where the field still has work to do.Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for selecting the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of the Specialty Section Pharmacogenetics & Pharmacogenomics, and should instead be submitted to the specialty section of Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or insufficient experimental validation, will not be included in this Research Topic.According to the Mission & Scope of the Journal (https://www.frontiersin.org/journals/pharmacology/about) studies that are purely statistical or predictive in nature, without providing novel insights into pharmacological mechanisms or drug development, are not within the scope of this journal. Topic editors: Evangelia Papadimitriou, Georgia Ragia, Antonis Goulas, Vangelis G Manolopoulos Source: https://www.frontiersin.org/research-topics/80603/the-evolving-landscape-of-omics-based-biomarkers-in-precision-therapeutics